Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 04, 2025 20:00 ET | Source: Transcenta

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

PRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with...